SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO(R) (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO(R) (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid […]